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Abstract. Chronic periodontitis is an inflammatory disease
of tooth-supporting tissues associated with Porphyromonas
gingivalis. Expansion and invasion of this bacterium into the
periodontium  is associated with changes in the metabolome
of the oral cavity. Materials and Methods: Metabolomics
analysis of mouth washout and tongue swab samples based on
proton nuclear magnetic resonance (1H-NMR) method was
employed to determine metabolic status of the oral cavity in
chronic periodontal disease. Results: Mouth washout extracts
contained a total of 23 metabolites and tongue swab extracts
contained 17. Identified metabolites partially overlap with the
content of saliva and gingival crevicular fluid. The
colonization of the oral cavity of patients with periodontitis by
bacteria was manifested in the change in levels of eight
metabolites. Conclusion: NMR-based metabolomics analysis
is a potentially useful methodological approach for monitoring
the pathological processes observed in the oral cavity in the
course of periodontitis.
Chronic periodontal disease (CPD) is a bacterial-driven
inflammatory malady affecting tissues supporting the teeth (1,
2). Disease severity ranges from mild and reversible
inflammation of soft tissue of the gingiva to chronic destruction
of periodontal tissues, including periodontal ligaments and
alveolar bone, which leads to formation of periodontal pockets
with eventual exfoliation of teeth (3-5). CPD in adults is
associated with colonization and proliferation of the gram-
negative anaerobic bacterium Porphyromonas gingivalis in
periodontal gingival pockets. The presence of P. gingivalis, and
several other gram-negative anaerobic bacteria, i.e.
Agregatibacter actinomycetemcomitans, Prevotella intermedia,
Tannerella forsythia, Fusobacterium nucleatum, Campylobacter
rectus, Peptostreptococcus micros, Streptococcus intermedius,
Treponema denticola, Eikenella corrodens acting possibly in
concert with the absence of beneficial species and the presence
of certain immunological deficiencies in the host, appears to
play an essential role in disease severity and progression (6, 7).
The primary site of oral cavity colonization by P. gingivalis
includes the supragingival tooth surface and subgingival
crevice (the space between the tooth root and the gingiva). 
P. gingivalis represents a late colonizer of the oral cavity,
requiring antecedent organisms to create the necessary
environmental conditions. The antecedent bacterial species may
facilitate colonization by P. gingivalis via provision of
attachment sites for interspecies adherence, supply of nutrients,
and reduction of oxygen tension to the low levels required for
growth and survival of this obligate anaerobe (7-9).
P. gingivalis does not produce a single potent exotoxin,
but is equipped with a set of enzymes, e.g. proteinases,
hemolysins, peptidylarginine deiminase and cellular
constituents, such as fimbriae and lipopolysaccharides,
which along with toxic metabolites, have the potential to
impinge upon host tissue integrity thus causing destruction
of periodontal supporting tissues (5, 7, 10-12). The repertoire
of enzymes and metabolites that can be detrimental to the
host also includes phospholipase A, prostaglandins, alkaline
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and acid phosphatases, etc. (13-17) and volatile sulfur
compounds such as hydrogen sulfide, methylmercaptan, and
dimethyl sulfide, which are cytotoxic and can be responsible
for protein synthesis inhibition (18, 19).
Beyond the primary site of colonization, the oral cavity
provides a variety of surfaces to which P. gingivalis can
efficiently adhere or invade (13, 16). Previous studies have
reported detection of periodontopathic bacteria in tongue
coating in close association with those in dental plaque (20-
22) and periodontal conditions (23-25), indicating that
periodontopathic microorganisms in the tongue, equally to
dental plaque, are an important factor in the etiopathogenesis
of periodontal disease. Therefore, similarly to gingival
crevicular fluid (GCF), other oral fluids and surfaces may
also constitute a potential reservoir of a variety of
inflammatory mediators and tissue-destructive molecules
associated with increased host–bacterial interactions
compared to individuals with healthy periodontium (25-28).
Metabolomics is a method of choice for diagnosis of
different pathological conditions. It allows for comparison of
the signature of low molecular weight compounds
(MW<1,000-1,500 Da) in biological samples from healthy
and disease-affected individuals, mainly by employing
nuclear magnetic resonance (NMR) and mass spectrometry
(MS) combined with various separation techniques (29-34).
Salivary metabolomics studies have been conducted for the
detection of many diseases including oral cavity (35). The
total composition shown by analysis of salivary gland
products should reflect two metabolomes, i.e. first that of the
investigated individual, within which all metabolites are
associated with the health status, and second, that which
represents the oral microbiome. Therefore, the output of
different studies may differ due to the contribution of
different microbial metabolomes. Among many diseases,
metabolomics analysis of oral cavity samples allows
distinction between patients with different periodontal
diseases and healthy individuals (36-38).
The aim of our study was to demonstrate the feasibility of
NMR analysis in determining the metabolic status of the oral
cavity in CPD, in easily accessible samples of mouth
washout and tongue swab employing an untargeted
metabolomics profiling method.
Materials and Methods
Study participants. The study was carried out in accordance with
the Declaration of Helsinki and was approved by the Bioethics
Committee of the Jagiellonian University, Medical College in
Krakow, Poland (KBET/310/B/2012). Adult males and females from
Krakow, Malopolska area (Poland) were enrolled in this study. All
participants read and signed a written informed consent form prior
to inclusion in the study. The study group consisted of 30 donors
diagnosed with advanced CPD with a minimum of 20 natural teeth
present (aged 37-68 years; 11 males, 19 females). The control group
comprised 15 donors in good general health (aged 23-62 years; four
males and 11 females). Exclusion criteria included: diagnosis of a
medical condition which required pre-medication/pre-treatment
prior to dental visits and procedures; five or more decayed untreated
teeth at screening (cavities); diagnosis of other diseases of the hard
or soft oral tissues; use of antibiotics or antimicrobial drugs within
30 days prior to the first study visit; a history of systemic disease
e.g. rheumatoid arthritis, aspiration pneumonia, diabetes mellitus,
atherosclerosis or other uncharacterized systemic disease; pregnant
and lactating women; tobacco smokers; immune-compromised
individuals e.g. diagnosed with HIV, AIDS, taking immuno-
suppressive drug therapy, radio- and chemotherapy.
Clinical and periodontal examination. Each participant’s medical,
dental, and medication history was recorded by the clinician. The
diagnosis of CPD was confirmed by radiographs and peripheral
blood samples collected for routine laboratory tests. The following
parameters were examined to assess the periodontal status: aproximal
periodontal index (API), sulcus bleeding index (SBI), probing pocket
depth (PPD) and clinical attachment level (CAL). API was classified
as optimal at <25%, moderately good at 26-39%, average at 40-70%,
and poor at 71-100% and expressed as the average value per whole
oral cavity. SBI was classified as: normal/healthy periodontium at
<12%; mild inflammation (slight change in color, little change in
texture) at 13-20%; moderate inflammation (redness, edema and
hypertrophy) at 21-50%; chronic inflammation (marked redness and
edema/hypertrophy, spontaneous bleeding or ulceration) at 51-100%
and also expressed as the average value per whole periodontium.
PPD and CAL were assessed for five teeth including at least one
central incisor and one first molar in the group with periodontitis
group and for five random teeth in control group, using the following
classification: PPD>7 mm and CAL>5 mm advanced periodontitis;
PPD 5-7 mm and CAL 3-4 mm moderate periodontitis; PPD 3-5 mm
and CAL 1-2 mm mild periodontitis. All in individuals with
periodontal disease included in the study group were classified as
having chronic (advanced) periodontitis. In the control group, all
assessed parameters were within the reference range.
Sample collection. Participants were asked to refrain from eating or
drinking, excluding water, from 11:00 pm of the night preceding
sample collection and to brush their teeth and entire mouth in the
evening before the visit, but not on the morning of collection.
Tongue swabs were obtained before mouth washouts collection. A
sterile cotton-tipped swab was used to collect the specimen from the
external surface of the tongue, placed in a 1.5 ml sterile
polypropylene tube with phosphate-buffered saline (sterile PBS, pH
7.2) and kept for 15 min at 4˚C to dissolve the swab content in the
buffer. Next, the samples were frozen in a dry-ice bath and stored
at −80˚C until shipping to Wroclaw University of Technology
(Poland) for metabolomics analysis. To obtain mouth washout, 0.5
ml of sterile saline (0.9% solution of NaCl) was given to
participants to rinse the oral cavity for 20-30 seconds, then the
sample was collected in a 2 ml sterile polypropylene tube and
immediately frozen in a dry-ice bath until shipping for
metabolomics analysis. No preservatives were added to the samples.
Sample preparation for 1H-nuclear magnetic resonance (NMR)
measurements. Biological samples were thawed at room temperature
and vortexed. Each sample of 120 μl of mouth washout and 120 μl
of tongue swab in PBS were transferred to new Eppendorf tubes. The
biological samples were then centrifuged for 10 min at 4˚C at 13,845
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× g. After centrifugation, 100 μl of supernatant was transferred to a
new Eppendorf tube and mixed with 400 μl deuterium oxide (D2O)
and 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP) (0.3
mM), and then transferred to an NMR cuvette (5 mm, Type 5SP;
ARMAR GmbH, Leipzig, Saxony, Germany).
Proton NMR measurements. The NMR spectra of mouth washout
and tongue swab samples were recorded at 300 K using an Avance
II spectrometer (Bruker, GmBH Hamburg, Germany) operating at
proton frequency of 600.58 MHz. The CPMG pulse sequence with
water presaturation (cpmgpr1d in Bruker notation) was used for both
types of biological material. Spectra for each sample were collected
by 128 subsequent scans with relaxation delay of 3.5 seconds;
acquisition time of 2.73 seconds; time domain (TD) of 64k; spectral
width (SW) of 20.01 ppm. The 1H-NMR spectra were processed
with line broadening of 0.3 Hz and manually phased, baseline-
corrected using Mestrelab Research v 11.0, (MestReNova, Santiago
de Compostela, Spain). Chemical shift was adjusted to reference
signal of TSP at δ=0.00 ppm. The resonance signals were aligned
with the use of the correlation optimized warping algorithm (COW)
and the icoshift algorithm implemented in Matlab 2014a (Mathworks
Inc., Natick, MA, USA) (39,40). Probabilistic quotient normalization
(PQN) method was used for spectra normalization (41).
Processing for data analysis. Calculation of the relative integral of
any NMR-measured metabolite was obtained as a sum of data
points of the non-overlapping resonances (or a cluster of partly
overlapping resonances). The metabolite resonances were identified
according to assignments published in the literature, the v 8.2
Chenomx software (Chenomx Inc. Edmonton, Alberta, Canada) and
on-line databases (Biological Magnetic Resonance Data Bank
(www.bmrb.wisc.edu) and Human Metabolome Data Base
(www.hmdb.ca). Only those metabolites values that could be
calculated based on assumptions of non-overlapping resonances
were used for further analysis. A total of 21 mouth washout and 18
tongue swab metabolites were assigned. Data matrix was scaled by
unit variance scaling (UV, Autoscaling).
Multivariate data analysis. The Orthogonal Projections to Latent
Structures Discriminant Analysis (OPLS-DA) with a 7-fold cross-
validation procedure was performed to determine variation between
studied groups. Sample order in the data matrix was randomized.
The reliability of OPLS-DA models was assessed by cross
validation analysis of variance at a significance level α=0.05. The
importance of the variables explaining the part of X related to Y
were presented by VIPpred plot (Predictive Variable Importance for
the Projection). Multivariate analysis calculations were carried out
in SIMCA 15 software (Sartorius Stedim Biotech, Göttingen,
Lower Saxony, Germany).
Statistical data analysis. Calculated relative integral of metabolites
assigned for mouth washouts and tongue swabs were used for
univariate statistics. The Shapiro–Wilk test was calculated for each
variable at a significance level α=0.05. Depending on the results of
normality test, a parametric (Student’s t-test) or a nonparametric
(Mann–Whitney–Wilcoxon test) test was used, both at a
significance level α=0.05. The changes between relative integrals
of metabolites of studied groups were verified by average
percentage difference (APD) and median percentage difference
(MPD). APD and MPD were calculated in relation to values for the
control group, whereby a positive value refers to the value being
higher in the patient group and negative one being lower in the
patient group than in the control group. The boxplot data
visualization and receiver operating characteristics (ROC) curve
calculation (classical univariate ROC curve analyses) were prepared
with MetaboAnalyst 4.0 platform (42). The cutoff value for area
under the ROC curve (AUC-ROC) of 0.750 was implemented for
selection of the metabolites most predictive of CPD.
Results
The 1H-NMR measurements allowed assignment of 21
recognized and four unknown metabolites from tongue
swabs and mouth washouts as listed in Table I. 
The analysis of the tongue swabs by 1H-NMR method
detected 17 metabolites: acetate, acetone, creatine, ethanol,
glycerol, glycine, isopropanol, lactate, methanol, O-
phosphocholine, propionate, pyruvate, succinate, and four
unknown compounds. Among all these metabolites, only three
were of statistical significance: Unknown 1, isopropanol, and
glycerol (Table II). The first two metabolites were found at a
higher level and the third was reduced in the CPD group
compared to the control group. 
Analysis of the mouth washouts revealed the presence of
23 assigned metabolites, namely: acetate, acetoin, acetone,
alanine, choline, ethanol, formate, glucose, glycerol, glycine,
isopropanol, lactate, methanol, propionate, propylene glycol,
pyruvate, succinate, taurine, valine and unknown compounds
1-4 (Table I). Differences in levels of four metabolites were
statistically significant between healthy and study groups:
acetone, methanol and unknown 2 were lower, while that of
lactate was higher in CPD than in controls (Table III). 
The OPLS-DA analysis showed separation between
patient and healthy control groups with satisfactory
parameters (Figures 1 and 2; Table IV), where both models
passed the validation test at the level of p=0.05.
The identified metabolites were verified by the ROC curve
by their discrimination potential. The value of 0.75 of AUC-
ROC was utilized as the cutoff point for selection of
metabolites. According to this limit, metabolites such as
unknown 1, isopropanol, and glycerol were important based on
tongue swab samples (Table II). Moreover, for mouth washout,
acetone, methanol, lactate, unknown 2 and taurine passed the
determined critical value for the ROC curve (Table III).
Discussion
To date, metabolomics analysis pertinent to periodontitis has
focused only on the metabolome of saliva and GCF (43-47).
In this study, we investigated the metabolic status of the oral
cavity in CPD using easily accessible, simple to collect and
non-invasive sampling of mouth washouts and tongue
swabs. The changes in the metabolite levels presented in
Tables II and III seem to be related to two phenomena. First,
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to the activity of the consortium of microorganisms in the
oral cavity, which utilize various energy sources during
colonization and survival, and second, to the host response
to ongoing pathological processes. Eight metabolites
altogether can be used as potential markers of periodontitis-
associated processes, however, some of them (methanol and
isopropanol), which are considered as exogenous
compounds, were reported as endogenous metabolites of
saliva (43). Moreover, the trends in metabolite level changes
in the month washouts and tongue swabs did not always
match (Tables II and III). This might have been a result of
the methodology of sample collections. Whereas tongue
swabs were obtained through physical rubbing on the
mucosal surface, the mouth washouts involved gentle
rinsing of the oral cavity. A second reason may be
associated with the change in solubility or local
concentration of the metabolite and gingival response to
these stimuli. 
Lactic acid was a statistically important metabolite in
mouth washout samples. This metabolite is recognized as a
side product of oral microbiome activity, e.g. a carbohydrate
fermentation (48), due to poor hygiene of the oral cavity. On
the other hand, the presence of the Lactobacilli species was
associated with their protective function against pathogenic
strains (49). Interestingly, in the context of the analysis of
variation in trends for metabolites in mouth washout samples
from patients with CPD, a similar metabolic profile (formate,
propionate) to that found in this study was detected in
patients with generalized aggressive periodontitis (G-AgP)
(50). The analysis showed significantly increased
concentrations of lactic acid, while that of formic acid was
lower in comparison to the control group (50) and its
concentration was associated with P. gingivalis-positive sites.
Previous studies exploring the levels of antioxidants and
oxidative stress in serum, saliva, and GCF of patients with
CPD have shown elevated lipid peroxidation and a disturbed
antioxidant status (51-53). Although in this study, we did not
detect unambiguously any products of protein/lipid
peroxidation in CPD-derived mouth washouts, elevated level
of taurine was detected. We hypothesize that mobilization of
taurine within the oral cavity may constitute a protective
effect mediated by its antioxidative properties and
regeneration of inflammatory gingival tissue (54).
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Table I. Proton nuclear magnetic resonance (1H-NMR) resonance
signals with their chemical shift δ, multiplicity and identification, which
were used in data analysis for tongue swabs and mouth washouts.
No.             Resonance                     1H δ=(ppm)                 HMDB ID
                      signal
                  assignment             Tongue          Mouth                    
                                                   swabs          washout
1                    Acetate                1.91 (s)         1.92 (s)         HMDB00042
2                   Acetoin                     -               1.38 (d)         HMDB03243
3                   Acetone               2.22 (s)         2.21 (s)         HMDB01659
4                   Alanine                     -               1.48 (d)         HMDB00161
5                   Creatine               3.02 (s)               -               HMDB00064
6                   Choline                     -               3.20 (s)         HMDB01565
7                    Ethanol                1.17 (t)          1.18 (t)         HMDB00108
8                   Formate                     -               8.48 (s)         HMDB00142
9                   Glucose                     -               5.23 (d)         HMDB00122
10                 Glycerol              3.56 (m)        3.58 (m)        HMDB00131
15                 Glycine                3.55 (s)         3.56 (s)         HMDB00123
11              Isopropanol            1.16 (s)         1.17 (d)         HMDB00863
12                  Lactate                1.31 (d)         1.33 (d)         HMDB00190
13                Methanol              3.34 (s)         3.36 (s)         HMDB01875
14         O-Phosphocholine       3.21 (s)               -               HMDB01565
16               Propionate             1.04 (t)          1.06 (t)         HMDB00237
17          Propylene glycol              -               1.15 (d)         HMDB01881
18                 Pyruvate               2.36 (s)         2.37 (s)         HMDB00243
19                Succinate              2.39 (s)         2.41 (s)         HMDB00254
20                  Taurine                      -               3.41 (t)         HMDB00251
21                   Valine                       -               1.05 (d)         HMDB00883
22              Unknown 1             0.89 (t)          0.89 (t)               No ID
23              Unknown 2            1.25 (s)         1.25 (s)               No ID
24              Unknown 3            1.29 (m)        1.56 (q)               No ID
25              Unknown 4            3.71 (m)        3.02 (m)              No ID
Table II. Analysis of tongue swab samples showing average percentage
difference (APD), median percentage difference (MPD) and relative
standard deviation (RSD) of relative integrals for metabolites for the
study groups.
                                                                                                RSD
                                         APD            MPD         Controls       Patients
Tongue swabs                    (%)                (%)               (%)               (%)
Unknown 1a#*                 79.54            97.03           76.98           72.1
Propionate                        −0.34            −3.73           30.19           44.46
Isopropanola#*                 35.71            67.9              74.27           38.79
Ethanol                             −2.59            −4.26           18.94           19.24
Unknown 2                      34.32            32.15           90.55           69.92
Unknown 3                        4.46              4.85            45.29           49.99
Lactate                              28.9              16.39           37.94           49.4
Acetate                             34.74            70.65           86.45           81.6
Acetone                            −1.46            −2.04              9.25            12.17
Pyruvate                             8.46            −4.79           50.93           41.57
Succinate                       −13.28            −5.15           49.99           51.71
Creatine                              4.99            23.49           63.94           62.21
O-Phosphocholine             8.1               15.48           60.41           38.28
Methanola                        −8.11          −11.57           14.41           15.33
Glycine                            −5.07          −24.13           94.76           97.92
Glycerola#*                    −39.39          −51.15           29.67           39.79
Unknown 4a                   −37.56            14.23         129.64           77.83
aPredictive variable importance prediction value above 1.00.
*Statistically important metabolites. #Metabolites with area under the
receiver operating characteristics curve >0.75.
Acetone originates from breakdown of acetoacetate and α-
hydroxybutyrate, accompanying fatty acid degradation,
glycolysis, and pyruvate metabolism (55-57). Acetone mouth
odor is mainly associated with diabetes and halitosis, however,
its higher level in body fluids may be used in clinical
diagnostics (56-58). The metabolism of acetone is closely
associated with the production of lactic acid, which in this
study was increased, therefore can be the product, at least in
part of acetone biotransformation (57). Increased level of
isopropanol in samples from CPD-affected patients is rather
surprising, considering that it is used as a common disinfectant
and antiseptic agent. However, the positive correlation
between isopropanol and acetone was found, where acetone
can also be the product of isopropanol breakdown (56). 
In general, glycerol is a metabolite that can originate from
glucose, proteins, pyruvate, triacylglycerols, and other
metabolic pathways (59). A part of glycerol of biological
origin can also be derived from its use as an ingredient of
toothpaste. Surprisingly, its level was found to be
significantly decreased in CPD, and this phenomenon can be
explained by utilization of glycerol as a carbon source or an
osmoregulatory agent by bacteria and fungi (59) colonizing
the oral cavity during periodontitis. The literature data
showed that glycerol-3-phosphate, which is the product of
glycerol phosphorylation by glycerol kinase, was found to
be elevated in periodontal disease (25, 60).
The presence of methanol in the oral cavity remains in
conflict with its toxic properties. In general, methanol is
considered a toxic agent in mammals. However, it is
commonly found as an endogenous metabolite, especially in
exhaled breath (61,62). Very recently it was suggested that
methanol might regulate mammalian gene activity (63). The
role of methanol and its sources in humans are not well
known. However, anaerobic fermentation by bacteria in the
human gut associated with a pectin-rich plant diet is
considered the source of methanol (64). Another process is
the transformation of S-adenosyl methionine to methanol
(65). Therefore, the presence of methanol in the oral cavity
is not surprising and its lowered level in those with CPD
than in healthy individuals may be related to its use as a
carbon or energy source for bacteria associated with CPD.
All these metabolites might contribute to CPD and
determining the pattern of their changes could be helpful to
highlight specific biochemical disturbances associated with
the transition from oral health to dysbiosis observation in
CPD.
Conclusion
The current study was performed to recognize the feasibility
of using metabolomic analysis in tracing pathological
changes in the oral cavity during the transition from health
to CPD. Based on the multivariate models, ROC, and
statistical analysis, it may be possible to find correlation
between specific patterns of metabolite variation and the
activity of the microbial consortium in the oral cavity, which
utilize various energy sources during colonization.
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Table III. Analysis of mouth washout samples showing average
percentage difference (APD), median percentage difference (MPD) and
relative standard deviation (RSD) of relative integrals for metabolites
for the study groups. 
                                                                                                RSD 
                                         APD            MPD         Controls       Patients 
Mouth washout                  (%)                (%)               (%)               (%)
Unknown 1                      −7.78            51.49         109.02           68.61
Valine                               −7.12            42.26         133.92         122.95
Propionate                        10.56            59.98           87.8              41.82
Propylene glycol              20.98          −29.01         135.02         197.17
Isopropanol                        3.82            31.49         125.18         106.86
Ethanol                               9.84            −6.55           33.24           50.50
Unknown 2a#*             −153.25        −134.53         109.44           63.12
Lactate#*                        101.96            61.82           89.77         123.44
Acetoin                               0.08            −9.19         164.21         180.46
Alanine                             19.5              26.76         106.73           83.20
Unknown 3                    −15.72              1.62            99.33           82.00
Pyruvate                           17.81            36.44         129.55           77.07
Acetatea                         −26.89            10.9              83.76           44.98
Acetonea#*                     −23.71          −22.96           23.57           17.84
Succinate                            8.07          −35.7              47.43           96.88
Unknown 4a*                 −56.35          −38.07            99                 75.50
Choline                            −0.54              1.9            124.39           83.45
Methanola#*                   −37.52          −39.63           26.12           34.39
Taurine#                            57.47            77.4            122.29           88.10
Glycinea                         −26.66            29.13         105.12           58.54
Glycerol                           50.24              4.9              37.7            108.95
Glucose                            67.86            86.74         126.82         121.67
Formate                          −39.29          −53.64           84.46         132.82
aPredictive variable importance prediction value above 1.00.
*Statistically important metabolites. #Metabolites with area under the
receiver operating characteristics curve >0.75.
Table IV. Summary of Orthogonal Projections to Latent Structures
Discriminant Analysis (OPLS-DA) model parameters with CV-ANOVA
p-value.
Comparison           N    Apred  Aorth     R2X      R2Y         Q2      p-Value
Tongue swabs       34        1          2       0.363     0.757     0.391     0.026
Mouth washout    35        1          1       0.455     0.522     0.322     0.017
Apred: Number of predictive components; Aorth: number of orthogonal
components; R2X: cumulative fraction of the variation of X variables
explained by the model; R2Y: cumulative fraction of the variation of Y
variables explained by the model; Q2: cumulative fraction of the
variation of Y variables predicted by the model. 
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Figure 1. Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA) models for tongue swab samples (A), predictive variable importance
for the projection plot (B), boxplot for statistically important metabolites and these with area under the receiver operating characteristics curve
(AUCROC)>0.75 (C), univariate ROC curves for selected metabolites (D). 
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Figure 2. Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA) models for mouth washout samples (A), predictive variable importance
for the projection plot (B), boxplot for statistically important metabolites and/or these with area under the receiver operating characteristics
(AUCROC)>0.75 (C), univariate receiver operating characteristics (ROC) curves for selected metabolites (D). 
We conclude that CPD-associated bacterial have a higher
metabolic activity as revealed by changes of lactate, acetone,
isopropanol, glycerol and methanol levels in comparison to
commensal microbiota in a healthy mouth. We suggest that
these metabolites are potential candidate biomarkers of CPD
and propose NMR-based metabolomics analysis as a
potentially useful methodological approach for monitoring the
pathological processes observed in the oral cavity in the
course of this disease. Further insight is needed to confirm this
preliminary observation through a prospective study on a
larger cohort of patients with CPD matched by sex and age
with healthy individuals.
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